IBMI delegation to Israel: Israeli VCs expected to visit Taiwan with interest in partnerships and innovative startups

IBMI delegation led by Academician Chi-Huey Wong and Pan-Chyr Yang, General Counsel and Vice President of IBMI, visited Israel in May and met with more than 20 companies and institutions there, including three major venture capital firms- Pitango, aMoon, Alon, three education institutions- Hebrew University of Jerusalem, Israel Institute of Technology, Tel Aviv University and 15 companies in the field of digital health, medical device and biotechnology. The delegation aimed to explore collaboration opportunities ranging from capital investment, R&D in new drugs, clinical trials to startup incubation, having received a positive response from companies and institutions visited with strong interest in taking part in the Healthcare+ Expo the end of year for further discussions with Taiwan-based counterparts.

The visit was co-organised by Asher Yarden, Representative of the Israel Economic and Cultural Office in Taiwan, and the Science and Technology Division of Taiwan Representative Office in Israel. IBMI signed an MOU at the Healthcare+ Expo 2018 with Israel’s largest life science and high-tech industry association IATI to jointly promote bilateral industrial cooperation. In addition to two biggest startup incubators IATI and MINDUP, IBMI also spoke to CEOs at leading venture capital firms in Israel, such as Pitango, the largest one having funded over 250 companies with more than $2billion. All Israeli VCs that the delegation visited expressed their interest in Taiwan's innovative technologies and joint investment. They have committed to the visit to Taiwan and the Expo as well as evaluating opportunities to fund startups and partner with relevant stakeholders in Taiwan. 

In addition, Israel has dedicated to the development of telemedicine, medical informatics, cell therapy, and medical devices. During the visit, several Israeli associations and companies, such as the Israel Export Association, a listed company Allium-medical, Nasdaq-listed company Pluristem and Oramed, a company that develops oral insulin, were keen to connect to Taiwan with opportunities for R&D and technology licensing.

Information appearing on this website (images and texts, unless otherwise indicated) is the property of IBMI. To use or share, please indicate the source.
©Institute for Biotechnology and Medicine Industry (IBMI) All rights reserved.
Address:16F.-1, No.3, Park St., Nangang Dist., Taipei City 115, Taiwan (R.O.C.) Contact Number:(02)2655-8168 Fax:(02)2655-7978